Abstract
It is well known that muscles can waste away (atrophy) due to a lack of physical activity. Muscle wasting commonly presents with reduced muscle strength and an impaired ability to perform daily tasks. Several studies have attempted to categorize muscle atrophy into three main subgroups: physiologic, pathologic, and neurogenic atrophy. Physiologic atrophy is caused by the general underuse of skeletal muscle (e.g., bedridden). Pathologic atrophy is characterized as the loss of stimulus to a specific region (e.g., aging). Neurogenic atrophy results from damage to the nerve innervating a muscle (e.g., SMA, GBS). Mechanisms have been elucidated for many of these pathways (e.g., ubiquitin-proteasome system, NF-κB, etc.). However, many causes of muscle atrophy (e.g., burns, arthritis, etc.) operate through unelucidated signaling cascades. Therefore, this review highlights the underlying mechanisms of each subtype of muscle atrophy while emphasizing the need for additional research in properly classifying and identifying muscle atrophy.
Keywords: Muscle atrophy, physical inactivity, ubiquitin-proteasome system, corticosteroids, aging, stimulus.
Current Pharmaceutical Design
Title:Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Volume: 27 Issue: 27
Author(s): John Zizzo*
Affiliation:
- University of Miami Miller School of Medicine, Miami, FL, 33136,United States
Keywords: Muscle atrophy, physical inactivity, ubiquitin-proteasome system, corticosteroids, aging, stimulus.
Abstract: It is well known that muscles can waste away (atrophy) due to a lack of physical activity. Muscle wasting commonly presents with reduced muscle strength and an impaired ability to perform daily tasks. Several studies have attempted to categorize muscle atrophy into three main subgroups: physiologic, pathologic, and neurogenic atrophy. Physiologic atrophy is caused by the general underuse of skeletal muscle (e.g., bedridden). Pathologic atrophy is characterized as the loss of stimulus to a specific region (e.g., aging). Neurogenic atrophy results from damage to the nerve innervating a muscle (e.g., SMA, GBS). Mechanisms have been elucidated for many of these pathways (e.g., ubiquitin-proteasome system, NF-κB, etc.). However, many causes of muscle atrophy (e.g., burns, arthritis, etc.) operate through unelucidated signaling cascades. Therefore, this review highlights the underlying mechanisms of each subtype of muscle atrophy while emphasizing the need for additional research in properly classifying and identifying muscle atrophy.
Export Options
About this article
Cite this article as:
Zizzo John *, Muscle Atrophy Classification: The Need for a Pathway-Driven Approach, Current Pharmaceutical Design 2021; 27 (27) . https://dx.doi.org/10.2174/1381612824666210316102413
DOI https://dx.doi.org/10.2174/1381612824666210316102413 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Autoimmune Neuromuscular Disorders
Current Neuropharmacology An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?
CNS & Neurological Disorders - Drug Targets Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Current Drug Targets Inhibitors of Protein-Protein Interactions as Potential Drugs
Current Computer-Aided Drug Design Curcumin Exposure Modulates Multiple Pro-Apoptotic and Anti-Apoptotic Signaling Pathways to Antagonize Acetaminophen-Induced Toxicity
Current Neurovascular Research Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science